Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

The Eu­ro­pean Med­i­cines Agency on Fri­day held its ground against an­ti-amy­loid treat­ments, say­ing it will not rec­om­mend Ei­sai and Bio­gen’s Alzheimer’s drug Leqem­bi for ap­proval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER